Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies

被引:29
作者
Konstantinov, SM
Kaminsky, R
Brun, R
Berger, MR
Zillmann, U
机构
[1] DEUTSCH KREBSFORSCHUNGSZENTRUM,AG TOXIKOL & CHEMOTHERAPIE,D-69120 HEIDELBERG,GERMANY
[2] SWISS TROP INST,CH-4002 BASEL,SWITZERLAND
[3] DEUTSCH KREBSFORSCHUNGSZENTRUM,ZENT TIERLAB,D-69120 HEIDELBERG,GERMANY
关键词
alkylphosphocholines; chemotherapy; growth inhibition; hexadecylphosphocholine; trypanosomatidae; Trypanosoma brucei subspecies;
D O I
10.1016/S0001-706X(96)00628-6
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Tetradecylphosphocholine (TPC), hexadecylphosphocholine (HPC), hexadecylphospho(N-N-N-trimethyl)hexanolamine (HPC6), octadecylphosphocholine (OPC), and octadecyl-[2-(N-methylpiperidinio)ethyl]-phosphate (OMPEP) were investigated for antitrypanosomal activity in vitro and in vivo. OMPEP showed the best trypanocidal efficacy in vitro: it was superior to the model compound HPC and comparable to the reference compound alpha-DFMO. HPC showed moderate activity in vivo in terms of increased life expectancy (up to 35% in the acute NMRI-mouse model or 49% if combined with phenylbutazone) and increased packed cell volume, if administered daily. However, HPC and the other alkylphosphocholines failed to prolong survival time of treated mice if given intermittently. Phenylbutazone had no own trypanocidal effect but increased the efficacy of alkylphosphocholines in vitro and in vivo: the combination of HPC and phenylbutazone acted apparently synergistic. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:145 / 154
页数:10
相关论文
共 20 条
[1]   POLYAMINE METABOLISM - A POTENTIAL THERAPEUTIC TARGET IN TRYPANOSOMES [J].
BACCHI, CJ ;
NATHAN, HC ;
HUTNER, SH .
SCIENCE, 1980, 210 (4467) :332-334
[2]   In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors [J].
Bacchi, CJ ;
Brun, R ;
Croft, SL ;
Alicea, K ;
Buhler, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1448-1453
[3]   CULTIVATION IN A SEMI-DEFINED MEDIUM OF ANIMAL INFECTIVE FORMS OF TRYPANOSOMA-BRUCEI, TRYPANOSOMA-EQUIPERDUM, TRYPANOSOMA-EVANSI, TRYPANOSOMA-RHODESIENSE AND T-GAMBIENSE [J].
BALTZ, T ;
BALTZ, D ;
GIROUD, C ;
CROCKETT, J .
EMBO JOURNAL, 1985, 4 (05) :1273-1277
[4]   HEXADECYLPHOSPHOCHOLINE DIFFERS FROM CONVENTIONAL CYTOSTATIC AGENTS [J].
BERGER, MR ;
BETSCH, B ;
GEBELEIN, M ;
AMTMANN, E ;
HEYL, P ;
SCHERF, HR .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1993, 119 (09) :541-548
[5]  
BERGER MR, 1992, PROG EXP TUMOR RES, V34, P98
[6]   In vitro trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors [J].
Brun, R ;
Buhler, Y ;
Sandmeier, U ;
Kaminsky, R ;
Bacchi, CJ ;
Rattendi, D ;
Lane, S ;
Croft, SL ;
Snowdon, D ;
Yardley, V ;
Caravatti, G ;
Frei, J ;
Stanek, J ;
Mett, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1442-1447
[7]   DRUG-SENSITIVITY OF CHINESE TRYPANOSOMA-EVANSI AND TRYPANOSOMA-EQUIPERDUM ISOLATES [J].
BRUN, R ;
LUN, ZR .
VETERINARY PARASITOLOGY, 1994, 52 (1-2) :37-46
[8]  
HABERKORN A, 1979, ZBL BAKT-INT J MED M, V244, P331
[9]   IN-VITRO ASSAYS TO DETERMINE DRUG SENSITIVITIES OF AFRICAN TRYPANOSOMES - A REVIEW [J].
KAMINSKY, R ;
BRUN, R .
ACTA TROPICA, 1993, 54 (3-4) :279-289
[10]  
Kaminsky R, 1996, TROP MED INT HEALTH, V1, P255